Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Spruce Biosciences ( (SPRB) ) has provided an update.
Spruce Biosciences announced that on December 11, 2025, Tiba Aynechi, Ph.D. resigned from its board of directors and as Chair of the Compensation Committee, with her departure not stemming from any disagreements with the company. On the same day, the board approved a stock option repricing to reduce the exercise price of certain stock options to $104.13 per share, aiming to retain and motivate employees and directors without causing stock dilution or significant cash expenditures.
The most recent analyst rating on (SPRB) stock is a Buy with a $160.00 price target. To see the full list of analyst forecasts on Spruce Biosciences stock, see the SPRB Stock Forecast page.
Spark’s Take on SPRB Stock
According to Spark, TipRanks’ AI Analyst, SPRB is a Underperform.
Spruce Biosciences faces substantial financial challenges with declining revenues and persistent losses. Bearish technical indicators and unfavorable valuation metrics further weigh on the stock. The strategic acquisition of TA-ERT offers potential growth, but the financial instability remains a critical concern.
To see Spark’s full report on SPRB stock, click here.
More about Spruce Biosciences
Average Trading Volume: 569,924
Technical Sentiment Signal: Buy
Current Market Cap: $91.7M
Find detailed analytics on SPRB stock on TipRanks’ Stock Analysis page.